Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Subscribe To Our Newsletter & Stay Updated
